Bone Biologics
BBLG
7 hedge funds and large institutions have $183K invested in Bone Biologics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
163% more capital invested
Capital invested by funds: $69.7K → $183K (+$114K)
40% more funds holding
Funds holding: 5 → 7 (+2)
1.72% less ownership
Funds ownership: 5.22% → 3.5% (-1.7%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$45.1K |
| 2 |
HF
HRT Financial
New York
|
+$7.51K |
| 3 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$701 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.32K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.35K |
BBLG Hedge Fund Activity: Q3 2024 in Review
7 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q3 2024, worth a combined $183K — up 163% from $69.7K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBLG positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $45.1K. The largest seller was Tower Research Capital (TRC), cutting an estimated $6.32K.
- 7 institutional investors held Bone Biologics (BBLG) as of Q3 2024, up from 5 in Q2 2024.
- Funds reported $183K of Bone Biologics stock for Q3 2024, up 163% quarter-over-quarter.
- 2 funds opened new Bone Biologics positions in Q3 2024 and 0 closed out, a net change of +2 holders.
- The largest Bone Biologics buyer in Q3 2024 was Morgan Stanley, an estimated $45.1K added.
- The largest Bone Biologics seller in Q3 2024 was Tower Research Capital (TRC), an estimated $6.32K sold.
Based on aggregated 13F filings for Q3 2024.